News

Digital inhalers enhance asthma control and reduce severe exacerbations, offering promising benefits with minimal harm for patients struggling with adherence.

Biomarker-informed molecular guidance led to greater achievement of disease control compared with standard “best care” for IBD anti-TNF therapy.

Gregory Cote, MD, reviews SHARP trial data suggesting ERCP with miES does not reduce acute pancreatitis risk in acute recurrent pancreatitis and pancreas divisum.

A variety of influences and potential confounders exist to explain the increasing rates of impairment concordant with chronic obstructive pulmonary disease.

Virtual pulmonary rehabilitation enhances access and improves outcomes for COPD patients, demonstrating safety and effectiveness in individualized care.

FDA approves 12.5 mg chlorthalidone tablets, enhancing hypertension treatment options and aligning with clinical guidelines for better patient outcomes.

Our April 2025 month in review highlights significant advancements in endocrinology, including innovative therapies and FDA approvals that enhance diabetes management.

New research reveals Medicaid unwinding disrupts chronic medication access for young adults, risking health and treatment outcomes amid enrollment losses.

This analysis highlighted the cardiovascular safety of systemic psoriasis drugs using a prospective cohort trial design.

Anthony Kerbage, MD, explains the heightened risk of repeat screening colonoscopy among patients with a primary language other than English.

Our April 2025 month in review highlights breakthroughs in gene therapy, device innovations, and evolving treatment strategies for cardiology.

Mazen Noureddin, MD, MHSc, reviews findings from a phase 2 study of efimosfermin alfa (BOS-580) for F2/F3 fibrosis due to MASH.

These post-hoc analysis findings align with POETYK PSO-4 regarding deucravacitinib’s effectiveness in patients with psoriasis.

Findings from a posthoc analysis of 2 phase 3 trials suggest seladelpar monotherapy has similar safety and efficacy to seladelpar combined with UDCA.

AI enhances prediction, diagnosis, and treatment of allergic diseases including asthma, atopic dermatitis, and food allergies, offering personalized, efficient care.

UBX1325 exhibited noninferiority to aflibercept in difficult-to-treat diabetic macular edema, while maintaining a favorable safety profile in the ASPIRE study.

Fendrick describes patients’ desire for green screening options and reviews findings from a study comparing the environmental impact of screening tools.

This analysis suggests intake of riboflavin, also known as vitamin B2, shows an association with patients’ risk of developing psoriasis.

New research uncovers unique brain abnormalities linked to sleep disorders and deprivation, revealing insights into emotional and cognitive impacts.

New triple therapy BGF shows significant and clinically meaningful lung function improvement in patients with uncontrolled asthma, with full data readouts coming soon.

Zhang describes the importance of multidisciplinary care for preventing alcohol relapse post-transplant, citing success from Mass General’s LIFT Clinic.

Gold explains misconceptions about who is affected by EoE and describes the importance of understanding the impact of SDoH in this patient population.

Fendrick describes the importance of follow-up colonoscopy after a positive result on a noninvasive test and factors influencing follow-up rates.

FibroX showed superior performance, interpretability, and potential cost savings relative to FIB-4, improving risk stratification and management in MASLD.

Pontecorvi describes the unique features of the EndoZip system and reviews findings from a study on its use for treating obesity-related comorbidities.

Compared with non-users, the cannabis use cohort showed significantly greater risks of acute pancreatitis flare pancreatic cancer, and all-cause mortality.

Feuerstadt explains recent advances in treating recurrent C diff and reviews new data on the safety and administration of fecal microbiota, live-jslm (Rebyota).

Long-term childhood outcomes were comparable in biologic-exposed and unexposed infants born to mothers with inflammatory bowel disease.